"Ursodeoxycholic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.
Descriptor ID |
D014580
|
MeSH Number(s) |
D04.210.500.105.225.272.962 D04.210.500.221.430.342.925
|
Concept/Terms |
Ursodeoxycholic Acid- Ursodeoxycholic Acid
- Acid, Ursodeoxycholic
- Ursacholic Acid
- Acid, Ursacholic
- 3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid
- 3 alpha,7 beta Dihydroxy 5 beta cholan 24 oic Acid
- Ursodiol
- Deoxyursocholic Acid
- Acid, Deoxyursocholic
|
Below are MeSH descriptors whose meaning is more general than "Ursodeoxycholic Acid".
Below are MeSH descriptors whose meaning is more specific than "Ursodeoxycholic Acid".
This graph shows the total number of publications written about "Ursodeoxycholic Acid" by people in this website by year, and whether "Ursodeoxycholic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
2006 | 0 | 1 | 1 |
2020 | 0 | 1 | 1 |
2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ursodeoxycholic Acid" by people in Profiles.
-
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2023 Mar; 615(7950):134-142.
-
Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021 07; 66(7):2439-2451.
-
Current treatment options for nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 2019 05; 35(3):168-176.
-
New therapies in hepatitis C virus and chronic liver disease: antifibrotics. Clin Liver Dis. 2006 Nov; 10(4):881-900.
-
Randomized trial of prevention of biliary stent occlusion by ursodeoxycholic acid plus norfloxacin. Gastrointest Endosc. 1995 Jul; 42(1):103-4.